Neumora Therapeutics
Latest round
- Series B
Last raised
- Oct 2022
Total raised
- $612M
Investors
- 17
About Neumora Therapeutics
Neumora Therapeutics, Inc.Founded in 2019 in Watertown, US, Neumora Therapeutics specializes in the development of therapeutics addressing brain diseases. The company’s leadership includes CEO Henry Gosebruch.Neumora's core offerings include innovative therapeutics designed for brain diseases, utilizing a precision medicine approach to target biological pathways in the Central Nervous System (CNS).Neumora focuses its revenue generation on strategic partnerships and collaborations, entering licensing and co-development agreements to facilitate commercializing its therapeutic products.
Who invested in Neumora Therapeutics
17 investors across 2 rounds
See all investors in Neumora Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neumora Therapeutics
Who invested in Neumora Therapeutics?
Neumora Therapeutics has 17 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neumora Therapeutics raised?
Neumora Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Neumora Therapeutics last raise money?
Neumora Therapeutics's most recent round on record is a Series B, in Oct 2022.
What does Neumora Therapeutics do?
Neumora Therapeutics is a biotechnology company.
Where is Neumora Therapeutics headquartered?
Neumora Therapeutics is headquartered in Watertown, US.
Which VCs invest in companies like Neumora Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Neumora Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Neumora Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.